530 related articles for article (PubMed ID: 34625994)
21. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
23. State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.
Cramer P; Hallek M; Eichhorst B
Oncol Res Treat; 2016; 39(1-2):25-32. PubMed ID: 26890007
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
25. Management of unfit elderly patients with chronic lymphocytic leukemia.
Eichhorst B; Hallek M; Goede V
Eur J Intern Med; 2018 Dec; 58():7-13. PubMed ID: 30527922
[TBL] [Abstract][Full Text] [Related]
26. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
Yeung CCS; Shadman M
Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
28. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
Siddiqi T
Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Markers in the Era of Targeted Therapies.
Kang S; Ahn IE
Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
[TBL] [Abstract][Full Text] [Related]
30. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
31. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
[TBL] [Abstract][Full Text] [Related]
32. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
Bose P; Gandhi V
Fac Rev; 2021; 10():22. PubMed ID: 33718939
[TBL] [Abstract][Full Text] [Related]
33. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
34. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
35. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
36. [Chronic lymphocytic leukemia : treatment concepts in transition].
Eichhorst B; Hallek M
Internist (Berl); 2015 Apr; 56(4):374-80. PubMed ID: 25776793
[TBL] [Abstract][Full Text] [Related]
37. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
38. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
Innocenti I; Autore F; Pasquale R; Morelli F; Efremov DG; Laurenti L
Expert Rev Hematol; 2017 Dec; 10(12):1069-1076. PubMed ID: 29082795
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Czuczman MS; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Harris NL; Hoppe RT; Horwitz SM; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Saad AA; Sokol L; Swinnen LJ; Tsien C; Vose JM; Wilson L; Yahalom J; Zafar N; Dwyer M; Sundar H;
J Natl Compr Canc Netw; 2015 Mar; 13(3):326-62. PubMed ID: 25736010
[TBL] [Abstract][Full Text] [Related]
40. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]